everydayhealth.com
Stacking Biologics if You Have Crohn's Disease: Is It Safe? - Everyday Health
Some people with moderate-to-severe Crohn’s who don’t fully respond to one advanced therapy may hear about adding a second drug. This article explains when clinicians might consider that approach, the potential benefits for hard-to-treat disease or fistulas, and the safety concerns to weigh.
Adults with Crohn’s disease, especially those on biologics or small-molecule therapies, clinicians treating IBD, and caregivers of people with refractory or perianal Crohn’s disease.
What To Know
This Everyday Health article explains the idea of "biologic stacking" (adding a second biologic or small-molecule advanced therapy) for Crohn’s disease, summarizes expert views on potential benefits and increased infection risk, and notes that evidence is mainly from observational studies and clinical experience rather than large randomized trials.
Experts say stacking may be considered for people who get partial benefit from a first advanced therapy, have refractory disease after many treatments, have extraintestinal manifestations, or have perianal fistulizing disease.
Gut-specific agents (vedolizumab) combined with IL-23 inhibitors (e.g., risankizumab, guselkumab) are mentioned as combinations some clinicians find relatively appealing. The article stresses weighing risks (higher infection risk, limited trial data) and close monitoring when dual therapy is used.
The piece does not present new trial data or definitive safety conclusions; it reports clinician perspectives and limited real-world/observational evidence.
The article summarizes expert opinion and observational/real-world experience rather than randomized clinical trial results. It emphasizes individualized decision-making and careful monitoring; it does not provide treatment recommendations or new efficacy/safety data.
